Industry has stepped forward to commit its expertise and resources to work towards developing vaccines in 100 days.
This investment comes as the world strives to end COVID-19 and better prepare for future threats.
The announcement comes ahead of the UK Government hosting the Global Pandemic Preparedness Summit.
CEPI will provide up to US $8.7 million (AU $12.3million) to support the trial, led by the Murdoch Children’s Research Institute (MCRI), Australia, with support from PATH.
CEPI will provide funding of up to $12.5m to support the development of multi-epitope, nanoparticle-based vaccine candidates and advance the manufacturing process.
OSLO, Norway, SHANGHAI and KUNMING, China; 8 February 2022: CEPI, the Coalition for Epidemic Preparedness Innovations, today announced that it will expand its collaboration with Shanghai Zerun Biotechnology Co., Ltd. (Zerun Bio) and its parent company Walvax Biotechnology Co., Ltd. (Walvax), a public company listed on the Shenzhen Stock Exchange (300142.SZ) to advance the development of...
The aim is to use these new tools to improve global access to vaccines through reducing complex-cold chain requirements and potential vaccine wastage.
